Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
Crossref DOI link: https://doi.org/10.1007/s00280-020-04131-y
Published Online: 2020-09-04
Published Print: 2020-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wu, Fan http://orcid.org/0000-0001-8339-4049
Krishna, Gopal
Surapaneni, Sekhar
Text and Data Mining valid from 2020-09-04
Version of Record valid from 2020-09-04
Article History
Received: 13 May 2020
Accepted: 22 August 2020
First Online: 4 September 2020
Compliance with ethical standards
:
: F.W., G.K, and S.S. are employees and hold equity ownership in Bristol Myers Squibb.